Our news

16.12.2024

Neophore appoints Michael Shih as Chief Executive Officer

ºÚÁϳԹÏÍø appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international p…

22.05.2024

ºÚÁϳԹÏÍø closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

ºÚÁϳԹÏÍø closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…

11.04.2024

ºÚÁϳԹÏÍø presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.

The ºÚÁϳԹÏÍø team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…

01.02.2024

ºÚÁϳԹÏÍø raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

ºÚÁϳԹÏÍø raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…

Other news

CEO Jeff Roix spoke to BioCentury about how ºÚÁϳԹÏÍø Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…

APM Health: Interview with CEO, Jeff Roix

Scrip Emerging company profile: UK-based ºÚÁϳԹÏÍø, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…